首页> 外文期刊>Acta Haematologica >Association of busulfan and cyclophosphamide conditioning with sleep disorders after hematopoietic stem cell transplantation.
【24h】

Association of busulfan and cyclophosphamide conditioning with sleep disorders after hematopoietic stem cell transplantation.

机译:白血球和环磷酰胺调节与造血干细胞移植后的睡眠障碍相关。

获取原文
获取原文并翻译 | 示例
           

摘要

New indications and conditioning regimens for hematopoietic stem cell transplantation (HSCT) have emerged in the last 10 years. Previous studies have shown the association of HSCT with late effects such as sleep disorders. The aim of this study was to determine the prevalence and factors associated with sleep disorders following HSCT in a population considering these new trends. Sixty-one individuals 1-10 years after allogeneic HSCT were surveyed using the DSM-IV-TR criteria for sleep disorders. Factors related to conditioning and graft-versus-host disease were collected from medical records. A prevalence of sleep disorders of 26.2% was found. Busulfan-cyclophosphamide conditioning was an independent risk factor in a multivariate analysis (relative risk, RR: 3.74, 95% CI: 1.1-12.6; p = 0.03), which also included sex (RR: 2.37, 95% CI: 1.0-5.7; p = 0.05) and age (RR: 1.03, 95% CI: 0.99-1.07; p = 0.11). Sleep disorders were frequent following HSCT. Patients who were treated with busulfan-cyclophosphamide had a higher risk of developing this complication. Female sex was also possibly a risk factor.
机译:过去十年来出现了造血干细胞移植(HSCT)的新适应症和条件疗法。先前的研究表明,HSCT与诸如睡眠障碍之类的晚期效应相关。这项研究的目的是考虑这些新趋势,确定人群中HSCT后睡眠障碍的患病率和相关因素。使用DSM-IV-TR睡眠障碍标准对异基因HSCT 1-10年后的61位个体进行了调查。从病历中收集与调理和移植物抗宿主病有关的因素。发现睡眠障碍的患病率为26.2%。在多变量分析中,白消安-环磷酰胺调理是一个独立的风险因素(相对风险,RR:3.74,95%CI:1.1-12.6; p = 0.03),其中还包括性别(RR:2.37,95%CI:1.0-5.7) ; p = 0.05)和年龄(RR:1.03,95%CI:0.99-1.07; p = 0.11)。 HSCT后经常出现睡眠障碍。用环丁砜-环磷酰胺治疗的患者发生此并发症的风险更高。女性也可能是危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号